巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Cellectis SA

CLLS
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Cellectis SA - 延遲價格・最後更新於 26/01 7:32
最高位
7.020
最低位
6.400
開市價
--
前收市價
6.590
成交量(千)
27.65
成交額(百萬)
1.78
買入
6.510
賣出
6.540
每手股數
--
市值(百萬)
297.41
市盈率
--
息率
--
差價
--
52週高低
32.249 - 6.320
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Cellectis SA
證券代碼
CLLS.US
所屬板塊
Biotechnology
公司業務
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
發行量
43039180
公司總部
8 rue de la Croix Jarry
公司網址
http://www.cellectis.com
公司電話
+33 181691600
暫無內容

關於

Cellectis SA(CLLS.US)所屬的行業板塊為Biotechnology。
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
詳細公司背景可參考: http://www.cellectis.com